The efficacy of topical Marham-e-Akbar in chronic atopic dermatitis – an open-label interventional study

Q2 Pharmacology, Toxicology and Pharmaceutics

Drug metabolism and personalized therapy Pub Date : 2022-02-25 DOI:10.1515/dmpt-2021-0195

S. Imran, Mohd Khalid, Nazim Husain, Mohd. Qudratullah Khan, Shalina Shaikh

{"title":"The efficacy of topical Marham-e-Akbar in chronic atopic dermatitis – an open-label interventional study","authors":"S. Imran, Mohd Khalid, Nazim Husain, Mohd. Qudratullah Khan, Shalina Shaikh","doi":"10.1515/dmpt-2021-0195","DOIUrl":null,"url":null,"abstract":"Abstract Objectives Chronic atopic dermatitis (AD) is an inflammatory skin condition marked by intense pruritus, dry skin, and severe impact on the life quality of the patients. Conventionally, it is managed by using emollients, calcineurin inhibitors, and topical corticosteroids. In Unani medicine, eminent scholars advocated many drug formulations including topical Marham-e-Akbar for effective healing of AD but scientific evidence is scarce. Hence, this study was designed. Methods This was a single-arm clinical trial conducted on 30 participants aged 18–65 years suffering from chronic AD after obtaining written informed consent. The trial intervention was Marham-e-Akbar consisting of Murdār Sang (Plumbi oxidum); Sindūr (red lead); olive oil (Olea europaea oil); Kath (Acacia catechu extract); Safeda Kāshgari (Zinc oxide); Sirka (vinegar); and Phitkirī (alum) to be applied twice daily for 42 days. The objective parameters were SCORAD and DLQI, while the subjective parameters included itching, scaling, and erythema assessed on a customized VAS scale and 4-point Likert scale. Results The pre-post analysis inferred statistically significant attenuation in subjective parameters (itching, scaling, and erythema) and objective scales (SCORAD) and (DLQI) with p<0.001. Conclusions The study findings deduced that Marham-e-Akbar is effective in the amelioration of chronic atopic dermatitis and quality of life of the patients as well.","PeriodicalId":11332,"journal":{"name":"Drug metabolism and personalized therapy","volume":"1 1","pages":"289 - 294"},"PeriodicalIF":0.0000,"publicationDate":"2022-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Drug metabolism and personalized therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1515/dmpt-2021-0195","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Pharmacology, Toxicology and Pharmaceutics","Score":null,"Total":0}

引用次数: 2

Abstract

Abstract Objectives Chronic atopic dermatitis (AD) is an inflammatory skin condition marked by intense pruritus, dry skin, and severe impact on the life quality of the patients. Conventionally, it is managed by using emollients, calcineurin inhibitors, and topical corticosteroids. In Unani medicine, eminent scholars advocated many drug formulations including topical Marham-e-Akbar for effective healing of AD but scientific evidence is scarce. Hence, this study was designed. Methods This was a single-arm clinical trial conducted on 30 participants aged 18–65 years suffering from chronic AD after obtaining written informed consent. The trial intervention was Marham-e-Akbar consisting of Murdār Sang (Plumbi oxidum); Sindūr (red lead); olive oil (Olea europaea oil); Kath (Acacia catechu extract); Safeda Kāshgari (Zinc oxide); Sirka (vinegar); and Phitkirī (alum) to be applied twice daily for 42 days. The objective parameters were SCORAD and DLQI, while the subjective parameters included itching, scaling, and erythema assessed on a customized VAS scale and 4-point Likert scale. Results The pre-post analysis inferred statistically significant attenuation in subjective parameters (itching, scaling, and erythema) and objective scales (SCORAD) and (DLQI) with p<0.001. Conclusions The study findings deduced that Marham-e-Akbar is effective in the amelioration of chronic atopic dermatitis and quality of life of the patients as well.

查看原文本刊更多论文

外用Marham-e-Akbar治疗慢性特应性皮炎的疗效——一项开放标签介入研究

摘要目的慢性特应性皮炎(AD)是一种以强烈瘙痒、皮肤干燥为特征的炎症性皮肤疾病，严重影响患者的生活质量。通常，它是通过使用润肤剂、钙调磷酸酶抑制剂和局部皮质类固醇来管理的。在Unani医学中，著名学者提倡许多药物配方，包括局部用药Marham-e-Akbar，以有效治疗AD，但科学证据很少。因此，设计了本研究。方法:在获得书面知情同意后，对30名年龄在18-65岁的慢性AD患者进行单臂临床试验。试验干预是Marham-e-Akbar，由Murdār Sang (Plumbi oxidum)组成;Sindūr(红铅);橄榄油(Olea europaea oil);儿茶提取物;Safeda Kāshgari(氧化锌);Sirka(醋);和phitkiri(明矾)，每天使用两次，持续42天。客观参数为SCORAD和DLQI，主观参数为瘙痒、脱屑和红斑，采用定制的VAS量表和4点Likert量表进行评估。结果经前后分析，主观指标(瘙痒、结垢、红斑)和客观指标(SCORAD)、DLQI均有统计学意义的降低(p<0.001)。结论本研究结果表明，marhamm -e- akbar能有效改善慢性特应性皮炎患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug metabolism and personalized therapy Pharmacology, Toxicology and Pharmaceutics-Pharmacology, Toxicology and Pharmaceutics (all)

CiteScore

2.30

自引率

0.00%

发文量

期刊介绍： Drug Metabolism and Personalized Therapy (DMPT) is a peer-reviewed journal, and is abstracted/indexed in relevant major Abstracting Services. It provides up-to-date research articles, reviews and opinion papers in the wide field of drug metabolism research, covering established, new and potential drugs, environmentally toxic chemicals, the mechanisms by which drugs may interact with each other and with biological systems, and the pharmacological and toxicological consequences of these interactions and drug metabolism and excretion. Topics: drug metabolizing enzymes, pharmacogenetics and pharmacogenomics, biochemical pharmacology, molecular pathology, clinical pharmacology, pharmacokinetics and drug-drug interactions, immunopharmacology, neuropsychopharmacology.